United Therapeutics Corporation (BMV:UTHR)
Mexico · Delayed Price · Currency is MXN | Market Cap | 482.82B +33.9% |
| Revenue (ttm) | 55.12B +2.5% |
| Net Income | 22.91B +5.5% |
| EPS | 525.04 +9.0% |
| Shares Out | n/a |
| PE Ratio | 18.44 |
| Forward PE | 18.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12 |
| Open | 9,680.00 |
| Previous Close | 9,535.62 |
| Day's Range | 9,680.00 - 9,680.00 |
| 52-Week Range | 5,672.39 - 9,884.33 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About United Therapeutics
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre... [Read more]
Financial Performance
In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.
Financial numbers in USD Financial StatementsNews
United Therapeutics price target lowered to $695 from $710 at JPMorgan
JPMorgan lowered the firm’s price target on United Therapeutics (UTHR) to $695 from $710 and keeps an Overweight rating on the shares.
United Therapeutics Rising Ahead of Next Earnings Report
Shares of United Therapeutics Corporation (UTHR) gain 4,517% since Big Money bought big in 2004.
United granted FDA clearance to proceed with trial of Treprostinil-Iloprost SMI
United Therapeutics (UTHR) announced that the U.S. Food and Drug Administration, FDA, has granted clearance under the company’s Investigational New Drug application to proceed with a clinical trial of...
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administra...
United Therapeutics price target raised to $850 from $700 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on United Therapeutics (UTHR) to $850 from $700 and keeps an Overweight rating on the shares. United Therapeutics retains upside potential despite limi...
United Therapeutics price target raised to $850 from $700 at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders raised the firm’s price target on United Therapeutics (UTHR) to $850 from $700 and keeps an Overweight rating on the shares. Published first on…
United Therapeutics price target lowered to $697 from $708 at RBC Capital
RBC Capital lowered the firm’s price target on United Therapeutics (UTHR) to $697 from $708 and keeps an Outperform rating on the shares. The top questions from investors have been…
United Therapeutics announces new share repurchase program for up to $2B
United Therapeutics (UTHR) announced that the company’s Board of Directors has authorized a new share repurchase program for up to $2 billion of the company’s common stock, available through October…
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors...
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a pre...
United Therapeutics price target raised to $717 from $685 at Raymond James
Raymond James raised the firm’s price target on United Therapeutics (UTHR) to $717 from $685 and keeps an Outperform rating on the shares. The Liquidia (LQDA) settlement strengthens the 2027+…
United Therapeutics opens third designated xenograft production facility
United Therapeutics (UTHR) announced the opening of its third Designated Pathogen-Free facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Tex...
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pa...
United Therapeutics price target raised to $725 from $685 at Leerink
Leerink raised the firm’s price target on United Therapeutics (UTHR) to $725 from $685 and keeps an Outperform rating on the shares. The firm updated its model to account for…
United Therapeutics announces FDA clearance to proceed with SUMMIT trial
United Therapeutics (UTHR) announced that the U.S. Food and Drug Administration has granted clearance under the company’s investigational new drug application to proceed with the SUMMIT clinical trial...
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administra...
United Therapeutics price target raised to $368 from $321 at Goldman Sachs
Goldman Sachs raised the firm’s price target on United Therapeutics (UTHR) to $368 from $321 and keeps a Sell rating on the shares.
LifeSci upgrades Liquidia to Buy on overhang clearing settlement
LifeSci Capital upgraded Liquidia (LQDA) to Outperform from Market Perform with a $59 price target. The company announced a settlement with United Therapeutics (UTHR) that resolves all six pending law...
Liquidia price target raised to $33 from $30 at Wells Fargo
Wells Fargo raised the firm’s price target on Liquidia (LQDA) to $33 from $30 and keeps an Equal Weight rating on the shares after the company and United Therapeutics (UTHR)…
Liquidia upgraded at BTIG after ‘much more favorable’ than expected settlement
As previously reported, BTIG upgraded Liquidia (LQDA) to Buy from Neutral with a $70 price target after the company announced it reached a global settlement with United Therapeutics (UTHR) to…
Liquidia Stock (LQDA) Pops as $380.7M Deal Ends Legal Battle with United Therapeutics
Liquidia ($LQDA) stock jumped about 47% in Wednesday’s pre-market trading after the biopharmaceutical company focused on respiratory and vascular diseases announced a $380.7 million settlement with Un...
Liquidia to pay $175M UTHR after settlement agreement
Liquidia (LQDA) and United Therapeutics (UTHR) reached a global settlement agreement that resolves all pending litigation between the companies. YUTREPIA, or treprostinil, inhalation powder will remai...
Liquidia up 40% to $37.59 after settlement agreement with United Therapeutics
17:57 EDT Liquidia (LQDA) up 40% to $37.59 after settlement agreement with United Therapeutics (UTHR)
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that two oral and five poster presenta...
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court ...